

February 13, 2026

National Stock Exchange of India Limited, Listing Compliance Department Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Scrip Symbol: GALAXYSURF	BSE Limited, Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001 Scrip Code: 540935
--	---

Sub: Investor presentation on the Unaudited Financial Results for the quarter and nine months ended December 31, 2025.

Ref: Regulation 30 (2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

We are enclosing Investor Presentation on the Unaudited Financial Results for the quarter and nine months ended December 31,2025.

The information is also hosted in announcement section on the website of the Company at www.galaxysurfactants.com.

We request you to take the same on record.

Yours faithfully,
For **Galaxy Surfactants Limited**

Niranjan Ketkar
Company Secretary
encl: as above



Galaxy Surfactants Limited

Result Presentation
February'26

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Galaxy Surfactants Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This Presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

Galaxy Rebranding: From Identity to Intent



“Chemistry Creates Care” reflects the principles at the core of Galaxy’s business

“Everything our partners rely on - our quality, our reliability, and our technical depth-remains unchanged. What has evolved is how clearly, we articulate our purpose. Built on a strong foundation, our new identity reaffirms that at the heart of Galaxy is Chemistry Creates Care. Through cocreation, we enable our partners to stay ahead and lead in their markets.”


From an operational standpoint, the company continues to focus on strengthening existing capacities, while selectively expanding its global footprint. Galaxy is also sharpening its geographic focus, with increased attention on markets in Latin America, Asia-Pacific, North America & Europe alongside its established presence in India and other international regions.

The rebrand is a strategic investment aligned with **Galaxy’s Vision 2030**, designed to deepen client loyalty, attract future ready talent, and manifest ambitious growth defined by purpose as much as performance.

Mr. K. Natarajan, Managing Director & CEO



Chemistry Products and Equations of Trust with all Stakeholders - Employees, Partners, Investors and Communities



Creates Spirit of Innovation, Creation and Possibilities



Care People-first organization serving the Personal & Beauty Care, Home Care, and Wellness industries- with commitment to caring for the planet

Galaxy’s new brand identity is anchored in **‘Co-creating Care,’** reflecting our focus on collaboration, trust, and shared purpose. The refreshed visual identity represents precise chemistry aligned with human needs and aspirations.



215+ Product Grades

Performance Surfactants: 47+
Specialty Care Products: 168+



Extensive R&D Capabilities

100+ Members
R&D Centre
Pilot Plant
Product Application Centre



7 Strategically Located Facilities with Inhouse Project Execution Capabilities

5 in India
1 in Egypt
1 in US



Serving 1,500+ Clients



Presence across 80+ countries



2,000+ Employees across all our Facilities

Q3 & 9MFY26

Performance Highlights





Mr. K. Natarajan
Managing Director

"The quarter gone by reflects a resilient performance in Q3FY26 despite multiple market headwinds. Consolidated volumes remained flat on YoY, with high single-digit growth in Specialty Care Products offsetting softness in the Performance Surfactants segment.

EBITDA increased by 13% on YoY to Rs 124 crore, supported by stronger contributions from the Specialty segment in India and ROW region. Consequently, EBITDA/MT improved to Rs 20,156/MT reflecting a favorable product mix and disciplined cost management.

In India, domestic volumes grew in the mid-single digit YoY, driven by strong traction from Non-Tier-1 and D2C customers. While the Performance segment declined due to ongoing reformulation at a key Tier-1 account and temporary demand disruption following GST-related inventory adjustments in October month, the Specialty segment delivered a robust 35% YoY volume growth, cushioning Tier-1 softness and reinstating momentum across Tier-2 and Tier-3 accounts.

In the AMET region volumes declined in the high teens YoY, primarily due to heightened competitive intensity.

Meanwhile ROW region continued to support portfolio resilience, delivering mid-single digit YoY volume growth, led by healthy demand across Latin America and Europe in both Performance and Specialty segments.

Prestige Specialty products from the Company's Tri-K subsidiary continued to demonstrate strong momentum, enhancing the premium mix contribution. Although U.S. reciprocal tariffs weighed on India-origin Specialty exports during the quarter the recent tariff rate reduction is expected to mitigate this impact going forward.

With India's improving growth environment following GST reforms of AMET volumes in coming quarters, incremental benefits from the U.S.-India tariff revision, and continued premiumization of the Specialty portfolio, the Company remains confident of regaining growth momentum in the coming quarters."

Key Developments

Consolidated volumes for Q3FY26 remained flat YoY. Strong high-single-digit growth in the Specialty Care segment offsetting by a decline in Performance Surfactants

EBITDA increased by 13% YoY in Q3FY26. Consequently, EBITDA/MT improved to ₹20,156/MT, compared to ₹17,527/MT in Q3FY25, reflecting better margin realization and cost control

9MFY26 EBIDTA remained flat on YoY at Rs 376 Cr as compared to Rs 375 Cr in 9MFY25 and consequentially 9MFY26 EBITDA /MT stood at Rs 19,126/MT as compared to 9MFY26 at Rs 19,272/MT

Feedstock prices softened briefly during the quarter, supported by record palm oil production; however, the benefit was short-lived. On the cost side, lower logistics expenses and successful execution of cost-efficiency initiatives supported margin expansion and improved overall financial performance

India volumes grew in the mid-single digits YoY, supported by T2-T3 customers and strong growth in the Specialty segment

AMET volumes declined in the high teens YoY, primarily due to intensified local competition


RoW volumes grew in the mid-single digits YoY, driven by strong traction in LATAM and Europe

Segment Performance Highlights

Performance Surfactants Revenue

Q3FY26

₹ 841.2 cr




9MFY26

₹ 2,523.2 cr

Specialty Care Revenue


₹ 493.0 cr



₹ 1,432.1 cr

Total Revenue

₹ 1,334.3 cr



₹ 3,955.4 cr

Overall Volume flat on YoY

Region-wise Volume Performance

INDIA

Q3FY26



Mid single digit growth on YoY

9MFY26

Low single digit growth on YoY



High double digit decline on YoY

High single digit decline on YoY




Mid single digit growth on YoY


High single digit growth on YoY

Consolidated Performance


Total Revenue




EBITDA




PBT (Before Exceptional)




9MFY26





9MFY26



9MFY26



Revenue Performance



 Performance Surfactants
 Specialty Care Products

 MNC Customer
 Local & Niche Player
 Regional Players

 India
 AMET
 ROW

Consolidated Profit & Loss Statement

Particulars (Rs. In Crores)	Q3FY26	Q3FY25	Y-o-Y	Q2FY26	Q-o-Q	9MFY26	9MFY25	Y-o-Y
Net Revenue from Operations	1,329.5	1,041.7	27.6%	1,326.2	0.3%	3,933.6	3,078.7	27.8%
Other Income	4.8	4.0		5.8		21.8	18.1	
Total Revenue	1,334.3	1,045.7	27.6%	1,332.0	0.2%	3,955.4	3,096.8	27.7%
Cost of Material Consumed	998.5	717.6		1,001.3		2,942.5	2,077.2	
Employee's Benefits Expense	80.2	73.8		80.5		244.2	226.7	
Other Expenses	131.5	144.7		133.9		393.2	417.5	
EBITDA	124.2	109.6	13.3%	116.3	6.8%	375.5	375.4	0.0%
EBITDA Margin	9.3%	10.5%		8.7%		9.5%	12.1%	
Depreciation	30.7	27.7		29.8		89.8	82.0	
EBIT	93.5	81.9	14.1%	86.5	8.1%	285.7	293.4	-2.6%
Finance cost	8.5	5.0		7.3		22.4	13.0	
PBT (Before Exceptional)	84.9	76.9	10.4%	79.2	7.2%	263.3	280.3	-6.1%
Exceptional Item#	11.9	-		-		11.9	-	
PBT (After Exceptional)	73.0	76.9	-5.0%	79.2	-7.8%	251.5	280.3	-10.3%
Tax expense	14.1	12.3		12.7		46.5	51.3	
PAT	59.0	64.6	-8.8%	66.5	-11.3%	205.0	229.0	-10.5%
PAT Margin	4.4%	6.2%		5.0%		5.2%	7.4%	
Other Comprehensive Income	14.4	23.2		38.6		54.9	27.3	
Total Comprehensive Income	73.4	87.8	-16.5%	105.1	-30.2%	259.9	256.4	1.4%
EPS	16.63*	18.20*		18.75*		57.81*	64.60*	


Fatty Alcohol prices in this quarter decreased to an average price of \$ 2,588/MT vs Q2 when it stood at \$ 2,800/MT. The same was \$ 2,496/MT in Q3FY25

Standalone Profit & Loss Statement


Particulars (Rs. In Crores)	Q3FY26	Q3FY25	Y-o-Y	Q2FY26	Q-o-Q	9MFY26	9MFY25	Y-o-Y
Net Revenue from Operations	867.7	727.3	19.3%	919.0	-5.6%	2,660.7	2,187.0	21.7%
Other Income	3.9	5.5		13.1		23.5	19.8	
Total Revenue	871.6	732.9	18.9%	932.0	-6.5%	2,684.2	2,206.8	21.6%
Cost of Material Consumed	679.2	533.0		717.8		2,069.8	1,562.0	
Employee's Benefits Expense	43.4	42.5		44.6		134.3	130.5	
Other Expenses	83.3	96.7		86.6		249.3	287.4	
EBITDA	65.7	60.6	8.3%	82.9	-20.8%	230.8	226.8	1.8%
EBITDA Margin	7.5%	8.3%		8.9%		8.6%	10.3%	
Depreciation	18.7	17.0		17.9		54.7	50.1	
EBIT	46.9	43.6	7.6%	65.0	-27.8%	176.1	176.7	-0.3%
Finance cost	7.8	4.5		6.4		19.8	11.3	
PBT (Before Exceptional)	39.2	39.2	0.1%	58.6	-33.2%	156.3	165.5	-5.5%
Exceptional Item [#]	11.9	-		-		11.9	-	
PBT (After Exceptional)	27.3	39.2	-30.3%	58.6	-53.4%	144.4	165.5	-12.7%
Tax expense	7.6	9.8		12.5		36.5	35.7	
PAT	19.7	29.4	-33.0%	46.2	-57.3%	107.9	129.8	-16.8%
PAT Margin	0.9%	1.3%		1.3%		1.4%	1.6%	
Other Comprehensive Income	-0.1	0.2		-0.1		-0.4	0.6	
Total Comprehensive Income	19.6	29.6	-33.9%	46.1	-57.5%	107.5	130.3	-17.5%
EPS	5.56*	8.30*		13.03*		30.44*	36.60*	

Managing Volatility in Raw Material Prices and Currency...

Fatty Alcohol Prices (USD / MT)



INR / USD Prices



... through Robust Risk Management Practices



Thank You

Company



Chemistry Creates Care

CIN No: L39877MH1986PLC039877

Mr. Ruchir Soni

Email: Ruchir.Soni@galaxysurfactants.com

www.galaxysurfactants.com

Investor Relations Advisors :



CIN - U74140MH2010PTC204285

Mr. Mandar Chavan / Mr. Rahul Agarwal

mandar.chavan@sgapl.net /

rahul.agarwal@sgapl.net

+91 96993 82195 / +91 98214 38864

www.sgapl.net